Skip to content

A Study on the Analgesic efficacy of liposomal bupivacaine in Interscalene brachial plexus block for postoperative pain management after shoulder surgery

A Study on the Analgesic efficacy of liposomal bupivacaine in Interscalene brachial plexus block for postoperative pain management after shoulder surgery

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600119745
Enrollment
Unknown
Registered
2026-03-03
Start date
2026-03-09
Completion date
Unknown
Last updated
2026-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rotator cuff injury

Interventions

Group R:general anesthesia+Ropivacaine interscalene brachial plexus block
Group DR:general anesthesia+Liposomal bupivacaine interscalene brachial plexus block

Sponsors

Fuyang Tumor Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Age between 18 and 65 years old 2. Plan to schedule a shoulder arthroscopy surgery. 3. The patient has an American Society of Anesthesiologists (ASA) score of II to III. 4.The patient Those who voluntarily sign the informed consent form.

Exclusion criteria

Exclusion criteria: Patients with local anesthetic allergy, cervical spondylosis, drug or alcohol abuse, opioid dependence, as well as contraindications to general anesthesia and interscalene brachial plexus block.

Design outcomes

Primary

MeasureTime frame
Resting pain scores of anesthesia recovery room (PACU) at 0 hours, postoperative 4, 12, 24, 48, and 72 hours;

Secondary

MeasureTime frame
The time of the first administration of analgesics in postoperative patients;The time of the first administration of analgesics in postoperative patients;The incidence of postoperative nausea and vomiting;Length of hospital stay;The incidence of phrenic nerve palsy;movement-evoked pain scores for anesthesia recovery room (PACU) at 0 hours, postoperative 4, 12, 24, 48, and 72 hours;

Countries

China

Contacts

Public ContactWenxiu Zhao

Fuyang Tumor Hospital

zhaowenxiu2022@126.com+86 139 6556 3901

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 14, 2026